Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:13:54 24/05/2024 pm IST			5-day change	1st Jan Change
1,076 ^INR	-0.93%		+2.34%	+56.12%

24/05	Zydus Completes Patient Enrolment for Phase II Clinical Trial of Usnoflast in ALS Patients	MT
21/05	Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	MT

Cadila Healthcare Limited Appoints Apurva S. Diwanji as an Additional Independent Director

May 13, 2016 at 02:42 pm IST

Cadila Healthcare Limited announced that the board of directors at its meeting has appointed Mr. Apurva S. Diwanji as an additional independent director of the company for a period of five years from May 13, 2016 till May 12, 2021.

Latest news about Zydus Lifesciences Limited

Zydus Completes Patient Enrolment for Phase II Clinical Trial of Usnoflast in ALS Patients	24/05	MT
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	21/05	MT
Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit	21/05	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold	20/05	MT
Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024	17/05
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024	17/05	CI
Zydus Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	17/05	CI
Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	17/05	CI
Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	13/05	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	10/05	RE
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis	09/05	CI
Zydus Lifesciences Gets US FDA Final Nod for Acne Treatment Gel	09/05	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%	09/05	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	06/05	MT
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	29/04	CI
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	29/04	CI
Weak March Quarter Earnings Weigh Down Indian Equities on Friday	26/04	MT
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	26/04	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Tretinoin Cream USP, 0.1%	26/04	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original for the Financial Year 2018-19	25/04	CI
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	24/04	MT
China Medical System's Anti-Anaemia NDA Accepted in China	23/04	MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23/04	MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	23/04	CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	22/04	CI

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,076 INR

Average target price

989.4 INR

Spread / Average Target

-8.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+56.12%	13.04B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.04%	42.95B
OTSUKA HOLDINGS CO., LTD.	+16.92%	21.38B
SANDOZ GROUP AG	+18.33%	15.05B
CIPLA LIMITED	+19.27%	14.45B
ONO PHARMACEUTICAL CO., LTD.	-10.73%	6.72B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+7.31%	4.84B
KRKA, D. D.	+15.91%	4.27B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Cadila Healthcare Limited Appoints Apurva S. Diwanji as an Additional Independent Director

EPS Revisions